Comprehensive assessment of neurodegeneration and dementia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multi-center, longitudinal observational program enrolling adults aged 50–90 with a range of diagnoses (subjective cognitive impairment, MCI, Alzheimer's, Lewy body disease, Parkinson's disease with and without cognitive impairment, and healthy controls) across sites in Canada. Participants receive detailed baseline clinical and neuropsychological evaluations, genomics testing, and multimodal neuroimaging. Biological samples (blood, saliva, urine, feces, buccal cells, and cerebrospinal fluid) are collected, stored, and analyzed, with annual follow-up visits and planned re-evaluations at two later timepoints. A Time 3 substudy will recruit ~400 participants from non-dementia cohorts to extend longitudinal follow-up and biomarker characterization.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Has subjective or objective cognitive impairment
* Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from a caregiver/family member)
* Sufficient proficiency in English or French to undertake self report and neuropsychological testing
* Geographic accessibility to the study site
* Must have a study partner who can participate as required in the protocol (provide corroborative information)
* Up to 12 years of education
* Fits into one of the following groups: Cognitively Unimpaired, Subjective Cognitive Impairment, Mild Cognitive Impairment, Vascular Mild Cognitive Impairment, Parkinson's Disease, Parkinson's Disease with Mild Cognitive Impairment

Exclusion Criteria:

* The presence of other significant known chronic brain disease such as: moderate to severe chronic static leukoencephalopathy (including previous traumatic injury), multiple sclerosis, a serious developmental handicap, malignant tumors, Parkinson's disease (other than for the Parkinson's cohort), and other rarer brain illnesses
* Ongoing alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures
* Symptomatic stroke within the previous year
* Unable to undergo MRI scan due to medical contraindications or inability to tolerate the procedure

Where it's running

• University of Calgary
  Calgary, Alberta, Canada Recruiting
• University of Alberta Hospital
  Edmonton, Alberta, Canada Recruiting
• Djavad Mowafaghian Centre for Brain Health
  Vancouver, British Columbia, Canada Recruiting
• Veteran's Memorial Building
  Halifax, Nova Scotia, Canada Recruiting
• Hamilton General Hospital
  Hamilton, Ontario, Canada Recruiting
• St. Joseph's Health Care London
  London, Ontario, Canada Recruiting

Study contacts

• Study coordinator: Howard Chertkow, MD
• Email: howard.chertkow@mcgill.ca
• Phone: 514 340 8222

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• China HEAD: a large community study on healthy aging and dementia

  This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.

  Recruiting at 30 sites Fudan University · Beijing and 29 other locations · NCT07912710

• Aging Brain Health Initiative in Fujian

  This observational study will follow about 3,000 older adults in Fujian to see how Alzheimer's-related changes develop and to test new digital tests, biomarkers, and imaging tools for early diagnosis.

  Recruiting at 4 sites Fujian Medical University Union Hospital · Fushun, Fujian and 3 other locations · NCT07891429

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

• Exploring the effects of sleep and exercise on Alzheimer's risk

  This study is testing how good sleep and regular exercise might lower the risk of developing Alzheimer's disease over time.

  Recruiting University of Miami · Miami, Florida · NCT04855630

• Automated language analysis to help diagnose neurodegenerative diseases

  A multilingual AI-powered language test is being tried to see if speech and language patterns can help differentiate Alzheimer’s, frontotemporal dementia, Lewy body dementia, and Parkinson’s from healthy aging.

  Recruiting Istituti Clinici Scientifici Maugeri SpA · Bari · NCT07906769

• Photobiomodulation therapy for mild cognitive impairment and mild Alzheimer's disease

  This trial tests whether daily transcranial near-infrared light therapy, versus a sham device, can improve cognitive function in adults with mild cognitive impairment or mild Alzheimer's disease.

  Recruiting Beijing Tiantan Hospital · Beijing · NCT07835399

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.